934P - Dynamics of changes in endocrine status in adolescents with lymphoma

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Lymphomas
Presenter Elena Pak
Citation Annals of Oncology (2016) 27 (6): 313-327. 10.1093/annonc/mdw375
Authors E. Pak1, O. Kit2, E. Frantsiyants3, V. Dmitrieva4, O. Kozyuk1, I. Lysenko1, L. Vladimirova5
  • 1Department Of Hematology, Rostov Research Institute of Oncology, 344037 - Rostov on Don/RU
  • 2Surgical Department, Rostov Research Institute of Oncology, 344037 - Rostov on Don/RU
  • 3Laboratory Of Study Of Malignant Tumor Pathogenesis, Rostov Research Institute of Oncology, Rostov on Don/RU
  • 4Department Of Pediatric Surgery, Rostov Research Institute of Oncology, Rostov on Don/RU
  • 5Department Of Chemotherapy, Rostov Research Institute of Oncology, 344037 - Rostov on Don/RU

Abstract

Background

The purpose of the study was to analyze the endocrine status of patients with Hodgkin lymphoma (HL) before treatment and the effect of chemotherapy on sex, pituitary and glucocorticoid hormones.

Methods

Gonadal function, its regulation by tropic pituitary hormones and levels of prolactin and cortisol were studied by radioimmunoassay in 32 HL patients aged 12-21 years receiving chemotherapy.

Results

Before therapy females showed estradiol decreased by 10 times compared with the norm in follicular and luteal phases of the cycle, with testosterone increase by 3.7 times in phase I and by 10 times in phase II of the cycle. Follicle-stimulating hormone (FSH) was 10 times lower than the norm. Luteinizing hormone in the luteal phase was similar to the norm in all disease stages, and in the follicular phase it was decreased by 15 times in patients with stage III-IV disease, compared with the norm. Male patients, especially those with stage III-IV disease, showed low testosterone levels in the blood before treatment. Significant overproduction of estradiol was observed, especially in stages III-IV. FSH levels in stage III-IV patients were 11 times lower than the norm; cortisol content did not change in stages I-II, and in stages III-IV it was 2.5 times higher than the norm. Prolactin and progesterone levels were similar to the norm.

Conclusions

HL development in adolescents is accompanied by significant changes in levels of sex and pituitary hormones and cortisol depending on the disease stage. Chemotherapy provides high antitumor effect and normalizes the levels of circulating hormones that have changed before the treatment.

Clinical trial identification

Legal entity responsible for the study

Rostov Research Institute of Oncology

Funding

Ministry of Health of the Russian Federation

Disclosure

All authors have declared no conflicts of interest.